{"id":832986,"date":"2025-04-02T09:03:09","date_gmt":"2025-04-02T13:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/"},"modified":"2025-04-02T09:03:09","modified_gmt":"2025-04-02T13:03:09","slug":"oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"
\n

IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference.<\/p>\n

During the event, Josh and Andrea will discuss Oncocyte\u2019s innovative diagnostic technologies and will highlight the company\u2019s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions.<\/p>\n

Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged to reach out to their Needham sales representative to express interest.<\/p>\n

\n Event:<\/strong> 24th Annual Needham Virtual Healthcare Conference
Dates:<\/strong> April 7-10, 2025
Oncocyte Fireside Chat:<\/strong> April 7, 2025, 3:45 PM (ET)
Location:<\/strong> Virtual<\/p>\n

For more information about Oncocyte and its products, please visit www.oncocyte.com<\/u><\/a>.<\/p>\n

\n About Oncocyte<\/strong>
\n
Oncocyte is a diagnostics technology company. The Company\u2019s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft\u2122 is a clinical blood-based solid organ transplantation monitoring test. GraftAssure\u2122 is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO\u2122 is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI\u2122 is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients.<\/p>\n

\n For more information about our products, please visit the following web pages:<\/strong>\n <\/p>\n

\n VitaGraft Kidney\u2122 –\u00a0<\/strong>
\n
\n https:\/\/oncocyte.com\/vitagraft-kidney\/<\/strong>
\n <\/a>
\n
\n
\n <\/a>
\n VitaGraft Liver\u2122 –\u00a0<\/strong>
\n
\n https:\/\/oncocyte.com\/vitagraft-liver\/<\/strong>
\n <\/a>
\n
\n GraftAssure\u2122 –\u00a0<\/strong>
\n
\n https:\/\/oncocyte.com\/graftassure\/<\/strong>
\n <\/a>
\n
\n
\n <\/a>
\n DetermaIO\u2122 – <\/strong>
\n
\n https:\/\/oncocyte.com\/determa-io\/<\/strong>
\n <\/a>
\n
\n
\n <\/a>
\n DetermaCNI\u2122 –\u00a0<\/strong>
\n
\n https:\/\/oncocyte.com\/determa-cni\/<\/strong>
\n <\/a>\n <\/p>\n

\n VitaGraft\u2122, GraftAssure\u2122, DetermaIO\u2122, and DetermaCNI\u2122 are trademarks of Oncocyte Corporation.<\/strong>\n <\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Any statements that are not historical fact (including, but not limited to statements that contain words such as \u201cwill,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cmay,\u201d and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte\u2019s progress toward commercializing a regulated organ transplant rejection monitoring test kit, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and\/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte\u2019s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients\u2019 use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the \u201cRisk Factors\u201d and other cautionary statements found in Oncocyte\u2019s Securities and Exchange Commission (SEC) filings, which are available from the SEC\u2019s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.<\/p>\n

\n CONTACT:<\/strong>
\n
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte\u2019s innovative diagnostic technologies and will highlight the company\u2019s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions. Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged … <\/p>\n

Continue reading “Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832986","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte\u2019s innovative diagnostic technologies and will highlight the company\u2019s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions. Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged … Continue reading "Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T13:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2025-04-02T13:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":654,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==\",\"datePublished\":\"2025-04-02T13:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte\u2019s innovative diagnostic technologies and will highlight the company\u2019s progress toward commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach, positioning Oncocyte to lead the way in advancing transplant monitoring solutions. Investors wishing to attend the virtual fireside chat or schedule one-on-one meetings are encouraged … Continue reading \"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T13:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference","datePublished":"2025-04-02T13:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/"},"wordCount":654,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/","name":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==","datePublished":"2025-04-02T13:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTU0NiM2ODQ3MzM2IzUwMDExOTgzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncocyte-to-participate-in-24th-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832986"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}